In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.

The drug company says that postmenopausal women who switched from a placebo to Femara experienced a 69-percent reduction in the risk of their breast cancer returning.

The new data has been presented at the 28th annual San Antonio Breast Cancer Symposium in Texas and is the first time that an aromatase inhibitor has shown a benefit in starting therapy up to five years after the end of standard Tamoxifen treatment.